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To the Editor,
We appreciate Drs. Tamura and Satoh’s in-
terest in our work and the opportunity they give 
us to respond to their four questions. 
Firstly, as mentioned in the section methods 
of our study “… participants were selected based 
on age and self-reporting of ‘a doctor’s diagnosis’ 
of respiratory disease (ICD-10-CM diagnosis codes 
J00-J99). Individuals using inhalers (short or long 
acting b2 adrenergic and/or anticholinergics and/or 
corticosteroids) without ever having reported in the 
questionnaires ‘a doctor’s diagnosis’ of respiratory 
disease were also included as having ‘possible ob-
structive pulmonary disease’. Finally, among par-
ticipants, those reporting chronic obstructive pul-
monary disease (J44), asthma (J45) and emphysema 
(J43) were identified in order to perform additional 
subgroup analyses” [1]. Also, in Table 1 we present 
separately the characteristics of participants re-
porting a respiratory disease with ICD-10-CM 
diagnosis code J44, J45, J43 as well as those having 
“possible obstructive disease” (see above for defini-
tion). The category “others” refer to those reporting 
any other ICD-10-CM diagnosis code from J00-J99.
Secondly, in the EPIC-Greece study no infor-
mation has been collected so far on the reasons a 
specific medication is prescribed by doctors for 
any disease, COPD included. 
Thirdly, due to the study design no data 
are available on the administration period of 
steroids.
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Dear Editor,
We read with interest the report by Karakatsani 
and associates on corticosteroids and hip fracture 
risk in elderly respiratory patients: EPIC-Greece 
cohort [1]. We would like to ask four points. 
First, there are many “others” evaluated in this 
study, we do ask what the diagnoses of these 
patients were. Second, long-acting muscarinic 
antagonist is considered as a standard treatment 
for COPD patients. Therefore, we would like 
to ask what the purposes of administration of 
steroids for COPD patients were. Third, we do 
wonder whether not only the amount of steroid 
administrated but also the period during which 
the drug was administered may be related to 
exacerbation of osteoporosis. Please let us know 
whether there were data on the administration 
period of steroids. Fourth, we were surprised 
to read that the occurrence of hip fracture in 
patients treated with inhaled steroids was the 
same as that in those treated with oral steroids. 
If it is true, should the risk of hip fracture in 
patients who are treated with inhaled steroids 
be considered the same as that in those treated 
with oral steroids?
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Fourthly, probably there is a misunderstanding 
because we did not draw such a conclusion in 
our study. Comparing the risk of hip fracture 
between participants treated with inhaled ste-
roids versus those taking oral steroids was not 
among the objectives of the current study. Other 
studies, specifically designed, should further 
address this issue.
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